Related Experiment Video
Updated: May 16, 2026

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
Published on: August 11, 2021
Serotonin receptors of type 6 (5-HT6): from neuroscience to clinical pharmacology
Donatella Marazziti1, Stefano Baroni, Franco Borsini
1Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie, University of Pisa, via Roma, 67, I-56100 Pisa, Italy. dmarazzi@psico.med.unipi.it
Abstract:
The serotonin (5-HT) receptors of type 6 (5-HT6) are quite different from all other 5-HT receptors, as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop. A lot of controversies still exist regarding their binding affinity, effects of 5-HT6 ligands on brain catecholamines, behavioral syndromes regulated by them, and brain distribution. In spite of the lack of information on metabolic pattern of the various compounds, some of 5-HT6 receptor ligands entered the clinical development as potential anti-dementia, antipsychotic, antidepressant and anti-obese drugs. The present paper is a comprehensive review on the state of art of the 5-HT6 receptors, while highlighting the potential clinical applications of 5-HT6 receptor agonists/antagonists.
Related Concept Videos
G-protein Coupled Receptors
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Neurochemical Transmission: Sites of Drug Action
Drugs Affecting Neurotransmitter Release or Uptake
Antidepressant Drugs: MAOIs and Other Agents
Drugs Affecting Neurotransmitter Synthesis
